EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study

Prashant Changoer iD, Pepijn van Houten iD, Daniele Ceruti, Ilse van Engen-van Grunsven, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier

European Thyroid Journal · 01.06.2026 · 15 (3)

DOI: 10.1530/etj-26-0074 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Thyroid Journal, online erschienen am 08.06.2026. Verfasst von Prashant Changoer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Molecular testing is increasingly used in thyroid cancer (TC) to complement diagnostics and guide systemic therapy choices. However, real-world data on its clinical impact remain limited. We evaluated the molecular landscape, clinical actionability, and outcomes of matched therapy in patients with advanced TC.

Methods

We retrospectively assessed 103 patients with advanced TC who underwent panel-based molecular testing with potential treatment consequences at Radboud University Medical Center, Nijmegen, the Netherlands, between 2014 and 2024. Alterations were classified using the European Society of Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT), and details on matched treatment and follow-up were collected.

Results

Molecular testing was performed at diagnosis (51.5%; primarily anaplastic TC) or upon disease progression (48.5%; primarily differentiated and medullary TC). Most frequent alterations were TP53 (39.8%), NRAS (17.5%), BRAF (16.5%), PTEN (16.5%), and RET (11.7%). Potential targetable alterations (ESCAT level I–III) were detected in 62.1% of patients, and 32.0% harbored ESCAT level I or II alterations considered clinically actionable. Matched systemic therapy was initiated in 16 patients and demonstrated an objective response rate of 56.3% and a disease control rate of 68.8%. Durable responses were predominantly observed in patients with ESCAT level I or II alterations (BRAF, RET, and NTRK). Matched therapy was associated with a trend toward longer overall survival (123.0 vs 57.0 months; P = 0.058).

Conclusion

Molecular testing frequently revealed targetable alterations in patients with advanced TC, and matched therapies yielded meaningful clinical benefit. These findings underscore the value of precision medicine in TC and support broader implementation of molecular-guided treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedMaleAdultAgedProto-Oncogene Proteins B-rafPTEN PhosphohydrolaseMutationTumor Suppressor Protein p53Proto-Oncogene Proteins c-retGTP PhosphohydrolasesMembrane Proteins

Stichwörter der Autor:innen

molecular landscapeprecision medicinetargetable alterationsthyroid cancer

Substanzen

Proto-Oncogene Proteins B-rafPTEN PhosphohydrolaseBRAF protein, humanPTEN protein, humanTumor Suppressor Protein p53RET protein, humanProto-Oncogene Proteins c-retNRAS protein, humanGTP PhosphohydrolasesMembrane Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Research Center for Functional Genomics, Biomedicine and Translation Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ORCID-Profile: Prashant Changoer, Pepijn van Houten

Zitieren

APA

Changoer, P., van Houten, P., Ceruti, D., van Engen-van Grunsven, I., Walraven, J. E. W., Ottevanger, P. B., Jaeger, M., & Netea-Maier, R. T. (2026). Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study. European Thyroid Journal, 15(3). https://doi.org/10.1530/etj-26-0074

Vancouver

Changoer P, van Houten P, Ceruti D, van Engen-van Grunsven I, Walraven JEW, Ottevanger PB, et al. Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study. European Thyroid Journal. 2026;15(3). doi:10.1530/etj-26-0074

BibTeX
@article{Changoer2026,
  author = {Changoer, Prashant and van Houten, Pepijn and Ceruti, Daniele and van Engen-van Grunsven, Ilse and Walraven, Janneke E W and Ottevanger, Petronella B and Jaeger, Martin and Netea-Maier, Romana T},
  title = {Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study},
  journal = {European Thyroid Journal},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1530/etj-26-0074}
}
Kostenlos starten →